You are here: Industry Insights > AbbVie

News List

AbbVie keeps May TV focus on Humira, while Gilead spends big on HIV drugs fiercepharma
June 28, 2019
Will AbbVie back off Humira advertising now that it’s announced it will buy Allergan? Maybe. But for now, the Illinois drugmaker is showing no signs of slowing its long-running robust TV ad push for the world's best-selling drug.
After Roche, BMS surprises, what does AbbVie need to do to win FTC clearance for Allergan buy? fiercepharma
June 28, 2019
But now, as Yee put it, the Otezla roadblock “is a potential read-through that the FTC is being tougher on regulating competition,” and it could mean future dealmakers may need to be more careful.
Analysts rip into AbbVie, Allergan's $63B deal, citing culture clash, strategy concerns and more fiercepharma
June 28, 2019
AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan that’ll create a top-5 pharma giant. But analysts and investors were hardly impressed. One day after the announcement, feedback continues to pour in, with analysts questio
AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan expressbpd
June 27, 2019
AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since January 2018 over concerns about Humira Drugmaker AbbVie said that it would acquire Allergan for about $63 billion ...
AbbVie signs agreement to acquire Irish Botox maker Allergan for $63bn pharmaceutical-technology
June 27, 2019
AbbVie has signed a definitive transaction agreement to acquire Irish Botox maker Allergan.
AbbVie to Buy Allergan for $63B contractpharma
June 26, 2019
As Humira faces competition, diversifies portfolio with biggest name in medical aesthetics.
AbbVie pads Humira follow-up Skyrizi's blockbuster potential with positive 2-year data fiercepharma
June 12, 2019
AbbVie already has high hopes for newly approved immunology drug Skyrizi as its old megablockbuster Humira starts to fall.
AbbVie, Roche present positive Venclyxto results at ASCO pharmatimes
June 05, 2019
AbbVie and Roche have announced data from the CLL14 trial, evaluating Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia.
Patent litigation for adalimumab resolved in the US europeanpharmaceuticalreview
May 29, 2019
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients drugs
May 22, 2019
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page